This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now
by Zacks Equity Research
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks
by Zacks Equity Research
NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
by Zacks Equity Research
NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.
Company News for Sep 30, 2021
by Zacks Equity Research
Companies in the news are: CTAS, NCNA, GOVX, LCID
Why NuCana (NCNA) Might Surprise This Earnings Season
by Zacks Equity Research
NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NuCana (NCNA) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Should You Buy NuCana (NCNA) Ahead of Earnings?
by Zacks Equity Research
NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) second-quarter results are likely to reflect higher COVID-19 test sales.
Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC
by Zacks Equity Research
Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
by Zacks Equity Research
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
by Zacks Equity Research
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Immunic Gets FDA Allowance for Phase II Coronavirus Study
by Zacks Equity Research
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
Why NuCana (NCNA) Stock Might be a Great Pick
by Zacks Equity Research
NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will NuCana Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of NuCana
Top Ranked Momentum Stocks to Buy for May 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 28th.
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
by Sreoshi Bera
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.